Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC
Published on 2 June 2026
Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive metastatic triple-negative breast cancer
Dr Kevin Kalinsky speaks to ecancer about updated results from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab as first-line treatment for patients with PD-L1-positive metastatic triple-negative breast cancer.
He reports that the combination improved progression-free survival 2 compared with chemotherapy plus pembrolizumab, demonstrating sustained clinical benefit beyond first disease progression.
Dr Kevin Kalinsky explains that these findings provide further evidence that sacituzumab govitecan plus pembrolizumab may represent a new standard of care for previously untreated PD-L1-positive metastatic triple-negative breast cancer.